racotumomab

Home
Ligands
racotumomab

GtoPdb Ligand ID: 7995

Synonyms: 1E10 | Vaxira®

racotumomab is an approved drug (Cuba and Argentina (2013))

Comment: Racotumomab is an anti-idiotype therapeutic cancer vaccine directed against the ganglioside N-glycolil (NGc) GM3 [2,5], which has been identified on the cell surface of malignant cells from lung [4] and breast tumours [8], melanoma [10-11], and neuroectodermal pediatric tumours [6-7,12-13]. Racotumomab is being investigated for its antineoplastic activity.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

Summary
Biological activity
Clinical data
References

Bioactivity Comments
Treatment of tumour-bearing mice with racotumomab (1E10 mAb) induces a strong antitumor effect [1]. A search of patents covering this antibody failed to identify any binding affinity data, but the antibody's primary molecular target is bourne out by results from biological investigations.

Bioactivity Comments

Treatment of tumour-bearing mice with racotumomab (1E10 mAb) induces a strong antitumor effect [1]. A search of patents covering this antibody failed to identify any binding affinity data, but the antibody's primary molecular target is bourne out by results from biological investigations.